Benefits of high versus low dose upadacitinib as maintenance treatment in ulcerative colitis patients who were responders to 8-week induction with upadacitinib: Results from the U-ACHIEVE phase 3 maintenance trial

被引：0
|
作者：
Feagan, Brian [1 ]
Parkes, Gareth [2 ,3 ]
Juillerat, Pascal [4 ,5 ]
Gecse, Krisztina [6 ]
Yao, Xuan [7 ]
Zhou, Wen [7 ]
Deng, Huiwen [7 ,8 ]
Ilo, Dapo [7 ]
Gonzalez, Yuri Sanchez [7 ]
Higgins, Peter D. R. [9 ]
机构：
[1] Western Univ, Div Gastroenterol, London, ON, Canada
[2] Barts Hlth NHS Trust, London, England
[3] Barts & London Queen Marys Sch Med & Dent, London, England
[4] Inselspital Bern, Dept Visceral Surg & Med, Gastroenterol, Bern, Switzerland
[5] Bern Univ, Bern, Switzerland
[6] Amsterdam UMC, Locat AMC, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands
[7] AbbVie Inc, Chicago, IL USA
[8] Univ Illinois, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
[9] Univ Michigan, Div Gastroenterol, Ann Arbor, MI 48109 USA
来源：
SWISS MEDICAL WEEKLY | 2023年 / 153卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
IBD-1
引用
收藏
页码：2S / 2S
页数：1
相关论文
共 33 条
  • [31] Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials (vol 399, pg 2113, 2022)
    Danese, S.
    Vermeire, S.
    Zhou, W.
    LANCET, 2022, 400 (10357): : 996 - 996
  • [32] EFFICACY OUTCOMES OF PLACEBO MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO RESPONDED TO PLACEBO INDUCTION THERAPY: RESULTS FROM THE PHASE 3 COMMAND STUDY
    Atreya, Raja
    Ferrante, Marc
    Afzali, Anita
    Bamias, Giorgos
    Long, Millie D.
    Neimark, Ezequiel
    Levine, Phillip
    Cheng, Ling
    Kalabic, Jasmina
    Hecht, Patrick
    Vladea, Ramona C.
    Schreiber, Stefan
    GASTROENTEROLOGY, 2024, 166 (05) : S815 - S816
  • [33] Value of Low Dose IL-2 as Maintenance Following Consolidation Treatment or Autologous Transplantation in Acute Myelogenous Leukemia (AML) Patients Aged 15-60 Years Who Reached CR After High Dose (HD-AraC) Vs Standard Dose (SD-AraC) Cytosine Arabinoside During Induction: Results of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups
    Willemze, Roelof
    Suciu, Stefan
    Mandelli, Franco
    Halkes, Stijn J. M.
    Marie, Jean-Pierre
    Labar, Boris
    Venditti, Adriano
    Muus, Petra
    Mistrik, Martin
    Rotoli, Bruno
    Magro, Domenico
    Melillo, Lorella
    Bron, Dominique
    Fabbiano, Francesco
    Selleslag, Dominik L. D.
    Pastore, Domenico
    Trisolini, Silvia Maria
    Fazi, Paola
    Vandermaelen, Christelle
    Baila, Liliana
    Vignetti, Marco
    Amadori, Sergio
    de Witte, T. M.
    Meloni, Giovanna
    BLOOD, 2009, 114 (22) : 327 - 327
1234